MOTRN.

Middle of the Road News

Every side. No side.

THE REEL · MIDDAY

FDA ORDERS A VISION-LOSS WARNING ON OZEMPIC, WEGOVY AND OTHER GLP-1 DRUGS

Monday, November 9, 2026 · 2:34 PM CST

Watch the original reel on Facebook.

The FDA on Monday, Nov. 9, required makers of GLP-1 drugs for diabetes and weight loss — including Novo Nordisk's Ozempic and Wegovy and Eli Lilly's Mounjaro and Zepbound — to add a Warnings and Precautions note about NAION, a rare eye condition that can cause sudden, painless and sometimes permanent vision loss in one eye. The FDA pooled 126 trials with 134,253 patients and counted 15 probable NAION events, 10 on a GLP-1 drug: 6.4 versus 3.8 per 100,000 person-years. Europe's regulator said last year NAION may affect up to 1 in 10,000 people on semaglutide for a year. Novo Nordisk says the data do not establish cause and effect. No drug was withdrawn, recalled or restricted.

Should a rare risk like this change how these drugs are prescribed — or just how they are labeled?

#FDA#Ozempic#Wegovy#GLP1#Health#Diabetes#WeightLoss

Sources

Originally published on Facebook as a MOTRN reel, Nov 9, 2026.